Really enjoyed today’s presentation, and meeting fellow...

Really enjoyed today’s presentation, and meeting fellow Neurenites! I didn’t get the chance to meet Little T, but someone pointed him out to me — he didn’t look quite how I thought he would. He is not Little and I was expecting to see a Tech Bro but he looked like a very wizened investor.

Had a great chat with JP and another Director, Dr Jenny Harris, after the meeting, Jenny Harris has a very impressive resume and brings real value to the Board.
Below is my take on the AGM

At this stage I don't believe there will not be another BB Patrick Davies all but confirmed that during the meeting
There are numerous / many multiple indications 2591 could be considered for (aspirin for the brain)
The board is focused on building as much value in the shortest possible time and identifying the most commercially viable options
Neuren presents a very rare opportunity for BP to acquire a late-stage, relatively small biotech with huge potential
My opinion only Neuren is being dressed up to sell and HIE is going to form a big part of that value chain
MPS also presents massive potential and the FDA will approve 2591 if they replicate P11 results (if we get to that stage it will catapult the SP)
The narrative is 2 years but as we know anything can happen on any given day
Acadia are working very hard to have Trofenitide made available in countries like Australia

This is MOO and JP nor Dr Jenny Harris divulged any information that is not generally known to the public they were both very professional and extremely engaging.

Good Luck to everyone